Neurointerventional specialists are trained to use special non-surgical technologies or procedures to diagnose and treat diseases and disorders related to the brain, spinal cord and nerves. These procedures and technologies use image-guided catheters to treat the brain and spine without the use of surgical incisions.

Neurointerventional is a relatively new but growing specialty that uses minimally invasive procedures to diagnose and treat disorders of the blood vessels of the spine, neck and head. Working closely with neurologists and neurosurgeons, neurointerventionalists use microcatheters, stents, balloons and similar devices to diagnose/treat aneurysm, vascular formations, clots, strokes, etc.

In the past, certain conditions that would have required open surgery such as aneurysms, vascular malformations, and tumors of the head, brain, neck and spine can now be considered for a minimally invasive procedure that uses the veins and arteries of the body to reach the problem.

STAR™ Tumor Ablation System

The STAR™ Tumor Ablation System delivers meaningful pain relief and localized tumor destruction in a single treatment, often in an outpatient setting. The STAR™ Tumor Ablation system is used for treating Metastatic Spinal Tumors with targeted RadioFrequency Ablation (t-RFA).

Expand your range of treatment options

Any patient with focalized pain from a metastatic spinal tumor may be a candidate for t-RFA, several specific patient groups will likely benefit most from the procedure.

Patients Who Benefit from RF Spine Tumor Ablation with The STAR™ Tumor Ablation System 1-4.

Patients with focal pain from metastatic spinal tumor(s) may be a candidate for treatment. However, patients that are ideally suited include those with:

  • Radio-resistant tumors
  • Persistent and/or recurrent pain after radiation therapy
  • Posterior vertebral body tumors
  • Reached maximum radiation dose limit
  • Focalized pain preventing immobilization for treatment with palliative radiation
  • Cannot undergo other palliative treatments due to their concurrent systemic treatments or ongoing clinical trials
  • Risk of myelosuppression